15
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Intracellular Delivery of Doxorubicin by Iron Oxide-Based Nano-Constructs Increases Clonogenic Inactivation of Ionizing Radiation in HeLa Cells

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          In this study, we determined the potential of polyethylene glycol-encapsulated iron oxide nanoparticles (IONP CO) for the intracellular delivery of the chemotherapeutic doxorubicin (IONP DOX) to enhance the cytotoxic effects of ionizing radiation. The biological effects of IONP and X-ray irradiation (50 kV and 6 MV) were determined in HeLa cells using the colony formation assay (CFA) and detection of γH2AX foci. Data are presented as mean ± SEM. IONP were efficiently internalized by HeLa cells. IONP CO radiomodulating effect was dependent on nanoparticle concentration and photon energy. IONP CO did not radiosensitize HeLa cells with 6 MV X-rays, yet moderately enhanced cellular radiosensitivity to 50 kV X-rays (DMF SF0.1 = 1.13 ± 0.05 ( p = 0.01)). IONP DOX did enhance the cytotoxicity of 6 MV X-rays (DMF SF0.1 = 1.3 ± 0.1; p = 0.0005). IONP treatment significantly increased γH2AX foci induction without irradiation. Treatment of HeLa cells with IONP CO resulted in a radiosensitizing effect for low-energy X-rays, while exposure to IONP DOX induced radiosensitization compared to IONP CO in cells irradiated with 6 MV X-rays. The effect did not correlate with the induction of γH2AX foci. Given these results, IONP are promising candidates for the controlled delivery of DOX to enhance the cytotoxic effects of ionizing radiation.

          Related collections

          Most cited references62

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Cancer nanomedicine: a review of recent success in drug delivery

          Cancer continues to be one of the most difficult global healthcare problems. Although there is a large library of drugs that can be used in cancer treatment, the problem is selectively killing all the cancer cells while reducing collateral toxicity to healthy cells. There are several biological barriers to effective drug delivery in cancer such as renal, hepatic, or immune clearance. Nanoparticles loaded with drugs can be designed to overcome these biological barriers to improve efficacy while reducing morbidity. Nanomedicine has ushered in a new era for drug delivery by improving the therapeutic indices of the active pharmaceutical ingredients engineered within nanoparticles. First generation nanomedicines have received widespread clinical approval over the past two decades, from Doxil® (liposomal doxorubicin) in 1995 to Onivyde® (liposomal irinotecan) in 2015. This review highlights the biological barriers to effective drug delivery in cancer, emphasizing the need for nanoparticles for improving therapeutic outcomes. A summary of different nanoparticles used for drug delivery applications in cancer are presented. The review summarizes recent successes in cancer nanomedicine in the clinic. The clinical trials of Onivyde leading to its approval in 2015 by the Food and Drug Adminstration are highlighted as a case study in the recent clinical success of nanomedicine against cancer. Next generation nanomedicines need to be better targeted to specifically destroy cancerous tissue, but face several obstacles in their clinical development, including identification of appropriate biomarkers to target, scale-up of synthesis, and reproducible characterization. These hurdles need to be overcome through multidisciplinary collaborations across academia, pharmaceutical industry, and regulatory agencies in order to achieve the goal of eradicating cancer. This review discusses the current use of clinically approved nanomedicines, the investigation of nanomedicines in clinical trials, and the challenges that may hinder development of the nanomedicines for cancer treatment.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Gold nanoparticles as radiation sensitizers in cancer therapy.

            Among other nanoparticle systems, gold nanoparticles have been explored as radiosensitizers. While most of the research in this area has focused on either gold nanoparticles with diameters of less than 2 nm or particles with micrometer dimensions, it has been shown that nanoparticles 50 nm in diameter have the highest cellular uptake. We present the results of in vitro studies that focus on the radiosensitization properties of nanoparticles in the size range from 14-74 nm. Radiosensitization was dependent on the number of gold nanoparticles internalized within the cells. Gold nanoparticles 50-nm in diameter showed the highest radiosensitization enhancement factor (REF) (1.43 at 220 kVp) compared to gold nanoparticles of 14 and 74 nm (1.20 and 1.26, respectively). Using 50-nm gold nanoparticles, the REF for lower- (105 kVp) and higher- (6 MVp) energy photons was 1.66 and 1.17, respectively. DNA double-strand breaks were quantified using radiation-induced foci of gamma-H2AX and 53BP1, and a modest increase in the number of foci per nucleus was observed in irradiated cell populations with internalized gold nanoparticles. The outcome of this research will enable the optimization of gold nanoparticle-based sensitizers for use in therapy.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Nuclear targeting of gold nanoparticles in cancer cells induces DNA damage, causing cytokinesis arrest and apoptosis.

              By properly conjugating gold nanoparticles with specific peptides, we were successful in selectively transporting them to the nuclei of cancer cells. Confocal microscopy images of DNA double-strand breaks showed that localization of gold nanoparticles at the nucleus of a cancer cell damages the DNA. Gold nanoparticle dark-field imaging of live cells in real time revealed that the nuclear targeting of gold nanoparticles specifically induces cytokinesis arrest in cancer cells, where binucleate cell formation occurs after mitosis takes place. Flow cytometry results indicated that the failure to complete cell division led to programmed cell death (apoptosis) in cancer cells. These results show that gold nanoparticles localized at the nuclei of cancer cells have important implications in understanding the interaction between nanomaterials and living systems.
                Bookmark

                Author and article information

                Contributors
                Role: Academic Editor
                Journal
                Int J Mol Sci
                Int J Mol Sci
                ijms
                International Journal of Molecular Sciences
                MDPI
                1422-0067
                24 June 2021
                July 2021
                : 22
                : 13
                : 6778
                Affiliations
                [1 ]Department of Radiation Oncology, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, 68167 Mannheim, Germany; roxana.popescu@ 123456nipne.ro (R.C.P.); Miriam.Bierbaum@ 123456medma.uni-heidelberg.de (M.B.); Adriana.Grbenicek@ 123456medma.uni-heidelberg.de (A.G.); Frank.Schneider@ 123456umm.de (F.S.); Frank.Giordano@ 123456umm.de (F.A.G.); Carsten.Herskind@ 123456medma.uni-heidelberg.de (C.H.)
                [2 ]Department of Life and Environmental Physics, “Horia Hulubei” National Institute for Physics and Nuclear Engineering, 077125 Magurele, Romania
                [3 ]Department of Science and Engineering of Oxide Materials and Nanomaterials, Politehnica University of Bucharest, 011061 Bucharest, Romania; Bogdan.vasile@ 123456upb.ro (B.Ș.V.); ecaterina.andronescu@ 123456upb.ro (E.A.)
                [4 ]Department of Anatomy and Developmental Biology, Center for Biomedicine and Medical Technology, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, 68167 Mannheim, Germany; Hiltraud.Hosser@ 123456medma.uni-heidelberg.de
                [5 ]CEO, University Medical Center Freiburg, 79106 Freiburg, Germany; Frederik.wenz@ 123456uniklinik-freiburg.de
                Author notes
                [* ]Correspondence: dsavu@ 123456nipne.ro (D.I.S.); Marlon.Veldwijk@ 123456medma.uni-heidelberg.de (M.R.V.); Tel.: +40214046134 (D.I.S.); +49-621-383-3750 (M.R.V.)
                Author information
                https://orcid.org/0000-0002-0145-5176
                https://orcid.org/0000-0002-2267-6453
                https://orcid.org/0000-0002-2226-5849
                Article
                ijms-22-06778
                10.3390/ijms22136778
                8267614
                34202550
                f88ad210-8b59-4023-9057-f16217fc8dff
                © 2021 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( https://creativecommons.org/licenses/by/4.0/).

                History
                : 27 May 2021
                : 17 June 2021
                Categories
                Article

                Molecular biology
                radiosensitization,nanoparticles,iron oxide,polyethylene glycol,doxorubicin,drug delivery

                Comments

                Comment on this article